AV Rheum
Author Payment
Reprints and Translations
Duncan A. Gordon Award
JRheum Supplements
Follow jrheum on Twitter
Visit jrheum on Facebook
Follow jrheum on LinkedIn
Follow jrheum on RSS
OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies
Maarten Boers, Dorcas E. Beaton, Beverley J. Shea, Lara J. Maxwell, Susan J. Bartlett, Clifton O. Bingham III, Philip G. Conaghan, Maria Antonietta D'Agostino, Maarten P. de Wit, Laure Gossec, Lyn March, Lee S. Simon, Jasvinder A. Singh, Vibeke Strand, George A. Wells and Peter Tugwell
The Journal of Rheumatology February 2019, jrheum.181096; DOI: https://doi.org/10.3899/jrheum.181096
Maarten Boers
From the Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit; Department of Medical Humanities, VU University Medical Centre/EMGO+ institute, Amsterdam, the Netherlands; Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto; Centre for Practice-Changing Research, Ottawa Hospital Research Institute; Cardiovascular Research Methods Centre, University of Ottawa Heart Institute; Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa; Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario; McGill Centre for Outcomes Research and Evaluation, Montreal, Quebec, Canada; Division of Rheumatology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland; Medicine Service, VA Medical Center; Department of Medicine, School of Medicine, University of Alabama; Division of Epidemiology, School of Public Health, University of Alabama, Birmingham, Alabama; SDG LLC, Cambridge, Massachusetts; Division of Immunology/Rheumatology, Stanford University School of Medicine, Palo Alto, California, USA; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and UK National Institute for Health Research (NIHR) Leeds Musculoskeletal Biomedical Research Unit, Leeds, UK; Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint- Quentin University, Saint-Quentin en Yvelines; Sorbonne Université; Pitié Salpêtrière hospital, AP-HP, Rheumatology Department, Paris, France; Sydney Medical School, Institute of Bone and Joint Research; Department of Rheumatology, Royal North Shore Hospital, St Leonards, Australia. DEB, COB III, PGC, MAD, MPD, LG, LM, LS, JAS, VS, GAW, and PT are members of the executive of OMERACT, an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies. PGC is funded in part by the NIHR Leeds Biomedical Research Centre. The views expressed in this article are those of the authors and not necessarily those of the UK National Health Service, the NIHR, or the Department of Health. JAS is supported by the resources and use of the facilities at the VA Medical Center at Birmingham, Alabama, USA. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. LM is a principal investigator on the Australian Rheumatology Association Database, which has received armslength funding from Pfizer Australia, AbbVie Australia, Eli Lilly Australia, and Janssen Australia. M. Boers, MD, PhD, Professor of Clinical Epidemiology, Amsterdam UMC, Vrije Universiteit Amsterdam; D.E. Beaton, PhD, Senior Scientist, Institute for Work & Health, and Associate Professor, Institute Health Policy, Management and Evaluation, University of Toronto; B.J. Shea, PhD, Senior Scientist, Ottawa Hospital Research Institute, Clinical Epidemiology Program, and School of Epidemiology, Public Health and Preventive Medicine, Faculty of Medicine, University of Ottawa; L.J. Maxwell, PhD, University of Ottawa and Centre for Practice-Changing Research, Ottawa Hospital Research Institute; S.J. Bartlett, PhD, Professor of Medicine, McGill University, Centre for Outcomes Research and Evaluation, and Division of Rheumatology, Department of Medicine, Johns Hopkins University; C.O. Bingham III, MD, Division of Rheumatology, Department of Medicine, Johns Hopkins University; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre; M.A. D'Agostino, MD, PhD, AP-HP, Professor of Rheumatology, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; M.P. de Wit, PhD, OMERACT Patient Research Partner, and Amsterdam University Medical Centre, Department of Medical Humanities, Amsterdam Public Health; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; L. March, MBBS, PhD, Liggins Professor of Rheumatology and Musculoskeletal Epidemiology, Sydney Medical School, Institute of Bone and Joint Research, and Department of Rheumatology, Royal North Shore Hospital; J.A. Singh, MBBS, MPH, Professor of Medicine and Epidemiology, Department of Medicine at the School of Medicine, University of Alabama at Birmingham; L.S. Simon, MD, Co-Managing Director of SDG LLC; V. Strand, MD, Biopharmaceutical Consultant, Portola Valley, California, USA; G.A. Wells, MSc, PhD, Director, Cardiovascular Research Methods Centre, University of Ottawa Heart Institute, and Professor, Department of Epidemiology and Community Medicine, University of Ottawa; P. Tugwell, MD, MSc, Professor, Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, and Clinical Epidemiology Program, Ottawa Hospital Research Institute. Address correspondence to Dr. M. Boers, Department of Epidemiology and Biostatistics, Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands. Accepted for publication December 6, 2018.
ORCID record for Maarten Boers
Dorcas E. Beaton
ORCID record for Dorcas E. Beaton
Beverley J. Shea
Lara J. Maxwell
ORCID record for Lara J. Maxwell
Susan J. Bartlett
ORCID record for Susan J. Bartlett
Clifton O. Bingham
Philip G. Conaghan
Maria Antonietta D'Agostino
ORCID record for Maria Antonietta D'Agostino
Maarten P. de Wit
ORCID record for Maarten P. de Wit
Laure Gossec
Lyn March
Lee S. Simon
Jasvinder A. Singh
ORCID record for Jasvinder A. Singh
Vibeke Strand
ORCID record for Vibeke Strand
George A. Wells
Peter Tugwell
ORCID record for Peter Tugwell
Objective The Outcome Measures in Rheumatology (OMERACT) Filter 2.0 framework was developed in 2014 to aid core outcome set development by describing the full universe of "measurable aspects of health conditions" from which core domains can be selected. This paper provides elaborations and updated concepts (OMERACT Filter 2.1).
Methods At OMERACT 2018, we discussed challenges in the framework application caused by unclear or ambiguous wording and terms and incompletely developed concepts.
Results The updated OMERACT Filter 2.1 framework makes benefits and harms explicit, clarifies concepts, and improves naming of various terms.
Conclusion We expect that the Filter 2.1 framework will improve the process of core set development.
You may purchase access to this article. This will require you to create an account if you don't already have one.
The Journal of Rheumatology
Thank you for your interest in spreading the word about The Journal of Rheumatology.
You are going to email the following OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies
Message Subject (Your Name) has forwarded a page to you from The Journal of Rheumatology
Message Body (Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
Maarten Boers, Dorcas E. Beaton, Beverley J. Shea, Lara J. Maxwell, Susan J. Bartlett, Clifton O. Bingham, Philip G. Conaghan, Maria Antonietta D'Agostino, Maarten P. de Wit, Laure Gossec, Lyn March, Lee S. Simon, Jasvinder A. Singh, Vibeke Strand, George A. Wells, Peter Tugwell
The Journal of Rheumatology Feb 2019, jrheum.181096; DOI: 10.3899/jrheum.181096
Remember my user name & password.
Real-world Longterm Effectiveness of Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis Patients from the Rheumatic Diseases Portuguese Register
Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis
Increased Cardiovascular Risk and All-cause Death in Patients with Behçet Disease: A Korean Nationwide Population-based Dynamic Cohort Study
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.